How Cabometyx Targets Kidney Cancer
Cabometyx (cabozantinib) treats advanced renal cell carcinoma (RCC), the most common type of kidney cancer, by inhibiting multiple tyrosine kinases that drive tumor growth and spread. It blocks vascular endothelial growth factor receptors (VEGFR-1, -2, -3), which reduces blood vessel formation to tumors (anti-angiogenesis). It also targets MET and AXL receptors, halting cancer cell proliferation, survival, and metastasis.[1][2]
Mechanism in Kidney Cancer Cells
In RCC, tumors overexpress these kinases, promoting uncontrolled growth and invasion into nearby tissues or distant sites like lungs or bones. Cabometyx disrupts signaling pathways such as MAPK/ERK and PI3K/AKT, starving cancer cells of growth signals and inducing cell death. This multitarget approach addresses resistance seen in single-kinase inhibitors.[1][3]
How It's Used in Treatment
The FDA approved Cabometyx in 2016 for previously treated advanced RCC, based on the METEOR trial showing doubled progression-free survival (7.4 vs. 3.8 months) over everolimus. It's now first-line with nivolumab (Cabometyx + Opdivo regimen) per CheckMate 9ER trial, improving overall survival by 40%.[2][4] Dosed at 40-60 mg daily orally, continuously until progression or intolerance.
Comparison to Other Kidney Cancer Drugs
Unlike single-target TKIs like sunitinib (mainly VEGFR), Cabometyx's MET/AXL inhibition better controls aggressive, MET-driven RCC subtypes. It outperforms immunotherapy alone in some patients but pairs well with PD-1 inhibitors. Nexavar (sorafenib) is less effective post-treatment.[3][5]
| Drug | Key Targets | Role in RCC | Median PFS (months) |
|------|-------------|-------------|---------------------|
| Cabometyx | VEGFR, MET, AXL | 1st/2nd-line | 7-16 (combo) [4] |
| Sunitinib | VEGFR, PDGFR | 1st-line | 8-11 [5] |
| Everolimus | mTOR | 2nd-line | 4-5 [2] |
Common Side Effects and Patient Concerns
Patients report hypertension (from VEGFR block), diarrhea, fatigue, and hand-foot syndrome. Dose reductions occur in 60% due to toxicity, but severe events (grade 3+) affect 70% less than alternatives. Liver monitoring is key; rare perforations or bleeding risks rise with prior treatments.[1][2] No direct patent data on DrugPatentWatch.com for cabometyx mechanism, but generics face exclusivity until 2026.[6]
When Does Protection End?
Cabometyx patents expire around 2026-2030, with pediatric extensions possible. Exelixis holds core composition patents; ongoing litigation could delay biosimilars.[6]
Sources
[1]: Cabometyx Prescribing Information (Exelixis)
[2]: FDA Approval Summary
[3]: NEJM METEOR Trial
[4]: CheckMate 9ER Lancet
[5]: NCCN RCC Guidelines
[6]: DrugPatentWatch.com - Cabozantinib